Form 4: Tenaya Therapeutics CMO Executes Routine Stock Sale

Chief Medical Officer Whittemore Tingley sold 3,121 shares of Tenaya Therapeutics to cover tax obligations related to RSU vesting.

Summary

• Whittemore Tingley, Chief Medical Officer of Tenaya Therapeutics, sold 3,121 shares of common stock.
• The transaction occurred on May 18, 2026, at a price of $0.7936 per share.
• The sale was executed to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs) granted on January 24, 2025.
• Following this transaction, the reporting person maintains beneficial ownership of 215,497 shares, which includes 112,919 shares underlying unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to satisfy tax requirements rather than a discretionary divestment.

Positives

• The sale was a non-discretionary transaction specifically intended to cover tax liabilities, indicating it was not a signal of lack of confidence in the company.

Negatives

• The transaction reflects a reduction in direct equity holdings by a key executive.

Risks

• The company remains subject to market volatility and the inherent risks associated with clinical-stage biotechnology development.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine 'sell-to-cover' transactions are standard practice in the biotechnology sector, where equity-based compensation is a significant component of executive pay packages, and do not typically reflect changes in corporate strategy or outlook.

Comparison to Industry Standards

• The transaction aligns with standard industry practices for managing tax obligations related to equity vesting schedules.
• The sale volume is immaterial relative to the total outstanding shares of the company.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sale.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Insider Trading, Form 4, Biotech, Executive Compensation